`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`PFIZER INC.,
`Petitioner,
`
` v.
`
`
`
`SANOFI-AVENTIS DEUTSCHLAND GMBH,
`Patent Owner.
`
`
`
`
`Case IPR2019-00977
`Patent Number: 8,603,044
`
`
`
`
`
`PATENT OWNER’S MANDATORY NOTICES
`PURSUANT TO 37 C.F.R. § 42.8
`
`
`
`
`
`Patent Owner, Sanofi-Aventis Deutschland GmbH, hereby submits its
`
`mandatory notices pursuant to 37 C.F.R. § 42.8(a)(2).
`
`
`
`A. Real Party-In-Interest (37 C.F.R. § 42.8(b)(1))
`
`The real parties-in-interest are the following: Sanofi-Aventis Deutschland
`
`GmbH (patent owner of U.S. Patent No. 8,603,044 (“the ’044 Patent”)), Sanofi-
`
`Aventis U.S. LLC (exclusive licensee of the ’044 Patent), and Sanofi Winthrop
`
`Industrie (exclusive licensee of the ’044 Patent). Evidence supporting Sanofi-
`
`Aventis Deutschland GmbH’s status as the patent owner is found on the face of the
`
`’044 Patent.
`
`B. Related Matters (37 C.F.R. § 42.8(b)(2))
`The following judicial and/or administrative proceedings could affect, or be
`
`affected by, a decision in this proceeding:
`
`- Sanofi-Aventis U.S. LLC, Sanofi-Aventis Deutschland GmbH, Sanofi
`Winthrop Industrie v. Mylan GmbH, Biocon Ltd., Biocon Research Ltd.,
`Biocon Sdn. Bhd. and Biocon S.A., Case No. 2-17-cv-09105-SRC-CLW,
`U.S. District Court for New Jersey;
`
`- Sanofi-Aventis U.S. LLC, Sanofi-Aventis Deutschland GmbH, and Sanofi
`Winthrop Industrie v. Merck Sharp & Dohme Corp., Case No. 1-16-cv-
`00812-RGA-MPT, U.S. District Court for the District of Delaware;
`
`- Sanofi-Aventis U.S. LLC, Sanofi-Aventis Deutschland GmbH v. Eli Lilly
`and Company, Case No. 1-14-cv-00113-RGA-MPT, U.S. District Court
`for the District of Delaware;
`
`- Mylan Pharmaceuticals Inc. v. Sanofi-Aventis Deutschland GmbH,
`IPR2018-01670, Patent Trial and Appeal Board, U.S. Patent and
`Trademark Office, involving U.S. Patent No. 8,679,069;
`
`
`
`
`- Mylan Pharmaceuticals Inc. v. Sanofi-Aventis Deutschland GmbH,
`IPR2018-01675, Patent Trial and Appeal Board, U.S. Patent and
`Trademark Office, involving U.S. Patent No. 8,603,044;
`
`- Mylan Pharmaceuticals Inc. v. Sanofi-Aventis Deutschland GmbH,
`IPR2018-01676, Patent Trial and Appeal Board, U.S. Patent and
`Trademark Office, involving U.S. Patent No. 8,603,044;
`
`- Mylan Pharmaceuticals Inc. v. Sanofi-Aventis Deutschland GmbH,
`IPR2018-01678, Patent Trial and Appeal Board, U.S. Patent and
`Trademark Office; involving U.S. Patent No.8,992,486;
`
`- Mylan Pharmaceuticals Inc. v. Sanofi-Aventis Deutschland GmbH,
`IPR2018-01679, Patent Trial and Appeal Board, U.S. Patent and
`Trademark Office, involving U.S. Patent No.8,992,486;
`
`- Mylan Pharmaceuticals Inc. v. Sanofi-Aventis Deutschland GmbH,
`IPR2018-01680, Patent Trial and Appeal Board, U.S. Patent and
`Trademark Office, involving U.S. Patent No. 9,526,844;
`
`- Mylan Pharmaceuticals Inc. v. Sanofi-Aventis Deutschland GmbH,
`IPR2018-01682, Patent Trial and Appeal Board, U.S. Patent and
`Trademark Office, involving U.S. Patent No. 9,526,844;
`
`- Mylan Pharmaceuticals Inc. v. Sanofi-Aventis Deutschland GmbH,
`IPR2018-01684, Patent Trial and Appeal Board, U.S. Patent and
`Trademark Office, involving U.S. Patent No. 9,604,008;
`
`- Mylan Pharmaceuticals Inc. v. Sanofi-Aventis Deutschland GmbH,
`IPR2019-00122, Patent Trial and Appeal Board, U.S. Patent and
`Trademark Office, involving U.S. Patent No.8,992,486;
`
`- Pfizer Inc. v. Sanofi-Aventis Deutschland GmbH, IPR2019-00978, Patent
`Trial and Appeal Board, U.S. Patent and Trademark Office, involving
`U.S. Patent No. 8,603,044;
`
`- Pfizer Inc. v. Sanofi-Aventis Deutschland GmbH, IPR2019-00979, Patent
`Trial and Appeal Board, U.S. Patent and Trademark Office, involving
`U.S. Patent No. 8,679,069;
`
`
`
`3
`
`
`
`
`- Pfizer Inc. v. Sanofi-Aventis Deutschland GmbH, IPR2019-00980, Patent
`Trial and Appeal Board, U.S. Patent and Trademark Office; involving
`U.S. Patent No.8,992,486;
`
`- Pfizer Inc. v. Sanofi-Aventis Deutschland GmbH, IPR2019-00981, Patent
`Trial and Appeal Board, U.S. Patent and Trademark Office; involving
`U.S. Patent No.8,992,486;
`
`- Pfizer Inc. v. Sanofi-Aventis Deutschland GmbH, IPR2019-00982, Patent
`Trial and Appeal Board, U.S. Patent and Trademark Office, involving
`U.S. Patent No.8,992,486;
`
`- Pfizer Inc. v. Sanofi-Aventis Deutschland GmbH, IPR2019-00987, Patent
`Trial and Appeal Board, U.S. Patent and Trademark Office, involving
`U.S. Patent No. 9,604,008;
`
`- Pfizer Inc. v. Sanofi-Aventis Deutschland GmbH, IPR2019-01022, Patent
`Trial and Appeal Board, U.S. Patent and Trademark Office, involving
`U.S. Patent No. 9,526,844; and
`
`- Pfizer Inc. v. Sanofi-Aventis Deutschland GmbH, IPR2019-01023, Patent
`Trial and Appeal Board, U.S. Patent and Trademark Office, involving
`U.S. Patent No. 9,526,844.
`
`The ’044 Patent, U.S. Application No. 13/909,649, is a continuation of U.S.
`
`Patent Application No. 12/944,544, now U.S. Patent No. 8,679,069, which is a
`
`continuation of U.S. Patent Application No. 11/483,546, now U.S. Patent No.
`
`7,918,833, which is a continuation of U.S. Patent Application No. 10/790,225, now
`
`abandoned, and claims priority to GB Patent Application No. 0304822.
`
`No U.S. patents or U.S. patent applications claim priority to the ’044 Patent.
`
`
`
`The following additional U.S. patents and U.S. patent applications claim
`
`priority to one or more of the same application(s) to which the ’044 Patent claims
`
`
`
`4
`
`
`
`priority:
`
`• U.S. Patent Application No. 10/790,866
`
`• U.S. Patent Application No. 15/681,604
`
`• U.S. Patent Application No. 15/787,737
`
`• U.S. Patent Application No. 16/385,682
`
`• U.S. Patent Application No. 12/320,189, now U.S. Pat. No. 7,850,662
`
`• U.S. Patent Application No. 11/520,598, now U.S. Pat. No. 7,935,088
`
`• U.S. Patent Application No. 13/040,198, now U.S. Pat. No. 8,512,297
`
`• U.S. Patent Application No. 13/075,212, now U.S. Pat. No. 8,556,864
`
`• U.S. Patent Application No. 13/909,681, now U.S. Pat. No. 8,992,486
`
`• U.S. Patent Application No. 13/919,251, now U.S. Pat. No. 9,011,391
`
`• U.S. Patent Application No. 12/941,702, now U.S. Pat. No. 9,028,454
`
`• U.S. Patent Application No. 12/357,899, now U.S. Pat. No. 9,205,197
`
`• U.S. Patent Application No. 14/635,573, now U.S. Pat. No. 9,233,211
`
`• U.S. Patent Application No. 14/946,203, now U.S. Pat. No. 9,408,979
`
`• U.S. Patent Application No. 15/156,616, now U.S. Pat. No. 9,526,844
`
`• U.S. Patent Application No. 14/319,379, now U.S. Pat. No. 9,533,105
`
`• U.S. Patent Application No. 14/319,384, now U.S. Pat. No. 9,561,331
`
`• U.S. Patent Application No. 14/319,388, now U.S. Pat. No. 9,604,008
`
`• U.S. Patent Application No. 14/319,394, now U.S. Pat. No. 9,604,009
`
`
`
`5
`
`
`
`• U.S. Patent Application No. 14/319,381, now U.S. Pat. No. 9,610,409
`
`• U.S. Patent Application No. 14/319,371, now U.S. Pat. No. 9,623,189
`
`• U.S. Patent Application No. 15/180,148, now U.S. Pat. No. 9,623,190
`
`• U.S. Patent Application No. 15/180,141, now U.S. Pat. No. 9,775,954
`
`• U.S. Patent Application No. 14/319,377, now U.S. Pat. No. 9,827,379
`
`C. Lead and Back-Up Counsel and Service Information (37 C.F.R. §
`42.8(b)(3)-(4))
`
`LEAD COUNSEL
`Elizabeth Stotland Weiswasser
`Reg. No. 55,721
`Weil, Gotshal & Manges LLP
`767 Fifth Avenue
`New York, NY 10153
`elizabeth.weiswasser@weil.com
`Phone: 212-310-8022
`Fax: 212-310-8007
`
`
`
`BACK-UP COUNSEL
`Anish R. Desai
`Reg. No. 73,760
`Weil, Gotshal & Manges LLP
`767 Fifth Avenue
`New York, NY 10153
`anish.desai@weil.com
`Phone: 212-310-8730
`Fax: 212-310-8007
`Sudip K. Kundu
`Reg. No. 74,193
`Weil, Gotshal & Manges LLP
`767 Fifth Avenue
`New York, NY 10153
`sudip.kundu@weil.com
`Phone: 212-310-8562
`Fax: 212-310-8007
`Adrian C. Percer
`Reg. No. 46,986
`Weil, Gotshal & Manges LLP
`201 Redwood Shores Parkway
`Redwood Shores, CA 94065
`adrian.percer@weil.com
`Phone: 650-802-3124
`Fax: 650-802-3100
`
`6
`
`
`
`
`
`
`
`LEAD COUNSEL
`
`BACK-UP COUNSEL
`Brian C. Chang
`Reg. No. 74,301
`Weil, Gotshal & Manges LLP
`201 Redwood Shores Parkway
`Redwood Shores, CA 94065
`brian.chang@weil.com
`Phone: 650-802-3936
`Fax: 650-802-3100
`William S. Ansley
`Reg. No. 67,828
`Weil, Gotshal & Manges LLP
`2001 M Street, N.W., Suite 600
`Washington, D.C. 20036
`sutton.ansley@weil.com
`Phone: 202-682-7018
`Fax: 202-857-0940
`Matthew D. Sieger
`Reg. No. 76,051
`Weil, Gotshal & Manges LLP
`2001 M Street, N.W., Suite 600
`Washington, D.C. 20036
`matthew.sieger@weil.com
`Phone: 202-682-7177
`Fax: 202-857-0940
`
`Please address all correspondence to lead and backup counsel. Patent Owner
`
`
`
`
`
`
`
`
`consents to service by electronic mail at the following address:
`
`Sanofi.IPR.Service@weil.com.
`
`A power of attorney from Patent Owner is being submitted concurrently
`
`herewith.
`
`
`
`
`
`
`
`7
`
`
`
`Date: May 23, 2019
`
` Respectfully submitted,
`
`/Elizabeth Stotland Weiswasser/
`Elizabeth Stotland Weiswasser
`Reg. No. 55,721
`Lead Counsel for Patent Owner
`Weil, Gotshal & Manges LLP
`767 Fifth Avenue
`New York, NY 10153
`Phone: 212-310-8000
`
`
`
`8
`
`
`
`
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`
`The undersigned hereby certifies that on May 23, 2019, the foregoing
`
`PATENT OWNER’S MANDATORY NOTICES was served via electronic
`mail, upon the following:
`
`
`Jovial Wong
`WINSTON & STRAWN LLP
`1700 K Street, NW
`Washington, DC 20006
`JWong@winston.com
`
`
`Charles B. Klein
`WINSTON & STRAWN LLP
`1700 K Street, NW
`Washington, DC 20006
`cklein@winston.com
`
`
`Dan H. Hoang
`WINSTON & STRAWN LLP
`35 W Wacker Dr.
`Chicago, IL 60601
`dhoang@winston.com
`
`
`PfizerIPRs@winston.com
`
`
`
`
`
`
`/Timothy J. Andersen/
`Timothy J. Andersen
`Case Manager
`Weil, Gotshal & Manges LLP
`2001 M Street NW, Suite 600
`Washington, D.C. 20036
`timothy.andersen@weil.com
`
`9
`
`